Omega Therapeutics (NASDAQ:OMGA – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research report issued on Monday, RTT News reports. They presently have a $12.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 426.32% from the company’s current price. Several other […]
Omega Therapeutics (NASDAQ:OMGA – Free Report) had its target price trimmed by Chardan Capital from $12.00 to $7.00 in a research report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Chardan Capital also issued estimates for Omega Therapeutics’ FY2024 earnings at ($1.31) EPS. Separately, Wedbush reissued an […]
Omega Therapeutics, Inc. (NASDAQ:OMGA – Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,620,000 shares, a growth of 138.2% from the December 31st total of 1,520,000 shares. Based on an average daily trading volume, of 1,920,000 […]
First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models.